Daiichi Sankyo, AstraZeneca’s ENHERTU gets BTD for HER2 Low Metastatic Breast Cancer

ENHERTU received BTD to treat adult patients with unresectable or metastatic HER2 low breast cancer. Credit: Sharon McCutcheon from Pixabay